secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2021-09-23T23:59:59+00:00
Accession:  0001140361-21-032255
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 4.01, 5.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Brooklyn ImmunoTherapeutics appoints CMO Roger Sidhu, outlines gene editing strategy; appoints Marcum as auditor
--------------------------------------------------------------------------------

- Roger Sidhu appointed CMO effective Sept 20, 2021; receives option for 161,300 shares and RSU for 80,650 shares, base salary $447,200.
- Bylaws amended to remove CFO position; VP of Finance Sandra Gurrola serves as principal financial officer.
- Marcum LLP appointed as new independent auditor for FY2021 after dismissal of Baker Tilly.
- Shareholder update call: plans to use iMSCs for allogeneic bone marrow transplants, gene editing for solid tumors and monogenic disorders.
- Dr. Sidhu previously at Kite Pharma (Gilead), Roivant Sciences, Cell Design Labs, Amgen; M.D. from Queen's University.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036121032255/0001140361-21-032255-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036121032255/brhc10029142_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-21-032255

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer